Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

89.03
+4.315.09%
Pre-market: 90.241.21+1.36%07:38 EDT
Volume:2.10M
Turnover:188.43M
Market Cap:7.85B
PE:-44.29
High:95.08
Open:88.64
Low:88.00
Close:84.72
52wk High:110.18
52wk Low:15.86
Shares:88.17M
Float Shares:80.98M
Volume Ratio:1.97
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.22
PE(LYR):-45.07

Loading ...

Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121

THOMSON REUTERS
·
16 mins ago

Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial

THOMSON REUTERS
·
Yesterday

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Yesterday

Movement Alert|SPYRE THERAPEUTICS INC Rises 6.21% in Regular Trading, Trading at $89.915

Market Focus
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Sep 28

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 09

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 09

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

TIPRANKS
·
Sep 09

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live
·
Sep 08

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

TIPRANKS
·
Sep 08

Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint

Reuters
·
Sep 08

Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics Grants Inducement Awards of 2,106 Stock Options, 745 RSUs to New Employee

Reuters
·
Sep 05

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Sep 05

Spyre Therapeutics CEO Turtle Cameron Disposes of 15,000 Common Shares Worth $1.31 Million

Reuters
·
Sep 04

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

U.S. Research Roundup-CrowdStrike, Nvidia, Macerich

Reuters
·
Aug 27